Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10564679 | 1.00 | HTT (0.54) | HTTCA1CA2CA7CA9 | |
| SCHEMBL13595480 | 1.00 | HTT (0.54) | HTTCA1CA2CA7CA9 | |
| SCHEMBL7451566 | 0.89 | HTT (0.58) | HTTCA1CA2CA7CA9 | |
| SCHEMBL4551396 | 0.89 | HTT (0.42) | HTTCA1CA2CA7CA9 | |
| SCHEMBL7450571 | 0.87 | HTT (0.53) | HTTCA1CA2CA7CA9 | |
| SCHEMBL12136563 | 0.84 | HTT (0.41) | HTTCA1CA2CA7CA9 | |
| SCHEMBL4552159 | 0.82 | HTT (0.41) | HTTKMT2APDE4DMAPK1TSHR | |
| SCHEMBL12858801 | 0.81 | SLC6A2 (0.40) | HTTPDE4D | |
| SCHEMBL7448869 | 0.81 | HTT (0.50) | HTTCA1CA2CA7CA9 | |
| SCHEMBL7976000 | 0.81 | HTT (0.50) | HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005991-A1 | INTERMEDIATES OF 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSES | LIBRAMEDICINA, INC. (JP) | 2013-01-03 | — | — | US | claimed |
| EP-2388257-A1 | Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-ß-D-arabinofuranoses | LibraMedicina, Inc. (JP) | 2011-11-23 | — | — | EP | claimed |
| US-20110152542-A1 | PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSES | LIBRAMEDICINA, INC. (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2799432-B1 | Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses | LIBRAMEDICINA INC (JP) | 2016-09-21 | — | — | EP | disclosed |
| EP-2513081-B1 | PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSES | LIBRAMEDICINA INC (JP) | 2015-07-08 | — | — | EP | disclosed |
| EP-2799432-A1 | Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses | Libramedicina, Inc. (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-8420831-B2 | Intermediates of 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses | LIBRAMEDICINA, INC. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20130005991-A1 | INTERMEDIATES OF 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSES | LIBRAMEDICINA, INC. (JP) | 2013-01-03 | — | — | US | disclosed |
| US-8329925-B2 | Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses | LIBRAMEDICINA, INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-2388257-A1 | Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-ß-D-arabinofuranoses | LibraMedicina, Inc. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110152542-A1 | PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSES | LIBRAMEDICINA, INC. (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005991-A1 | INTERMEDIATES OF 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSES | PFAS, AFF1, FUT6 | HTT 3573/4885CA1 1756/4885CA2 3951/4885 |
| US-20110152542-A1 | PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSES | PFAS, FUCA2, UGT1A6 | HTT 3791/4885CA1 1785/4885CA2 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.